• Axelar AB, of Stockholm, Sweden, part of the Karolinska Development AB portfolio, reported preliminary interim results from its Phase II study of AXL1717, indicating that the small-molecule IGF-1 receptor inhibitor is effective in treating patients with non-small-cell lung cancer.